1. Scrip
  2. >>Business
  3. >>Strategy

Boehringer’s Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire

 
• By Joseph Haas

The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.

Development_Strategy
BI looks to external innovation to bolster its therapeutic focus areas

In an interview with Scrip,Boehringer Ingelheim International GmbH’s top business development executives offered their views on conducting transactions amid a pandemic, why a company usually focused on partnerships has bought three cancer biotechs in recent years, and how it generally views major M&A.

Having been with the family-owned firm for about 15 years, Ioannis Sapountzis has graduated from leading US business development and licensing to overseeing BI’s global deal-making activity. (Also see "Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis" - Scrip, 30 June, 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

 
• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.